Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
The purpose of this study is to find out if the drug, Cabozantinib, is safe and tolerable in pediatric patients with refractory and/or recurrent high grade gliomas (HGG) who have previously received radiation therapy. We are also looking to see if the drug has an effect on the rate at which the tumor grows at 6 months.
The purpose of this study is to test the safety, tolerability and efficacy of carbozantinib in refractory and/or recurrent pediatric high-grade gliomas in children who have previously received radiation therapy.
- IRB Number: 1702306189 (IUSCC-0601)
- Research Study Identifier: TX7541
- Principal Investigator: Scott Coven
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required